Faculty ProfilesMeyeon Park, MD, MAS
My research focuses on the early diagnosis of kidney hypoxia, injury, and disease and the influence of cardiovascular disease on kidney disease onset and progression. Clinically, I see patients with all manifestations of hypertension and kidney disease, with a special focus on patients with polycystic kidney disease. I am the medical director of the UCSF PKD Center of Excellence and principal investigator of the UCSF Cardiovascular Risk After Kidney Transplantation (CARAKTER) study.
College: Harvard College
Medical School: University of Pennsylvania School of Medicine
Other Graduate Training: University of California, San Francisco, MAS
Internal Medicine Residency: Yale-New Haven Hospital
Nephrology Fellowship: University of California, San Francisco
Education and Training
|Location||Degree or Training||Specialty||Date|
|University of California, San Francisco||Nephrology fellowship||2013|
|University of California, San Francisco||M.A.S. in Clinical Research||Graduate Division (Advanced Training in Clinical Research)||2012|
|Yale-New Haven Hospital||Internal Medicine Residency||2009|
|University of Pennsylvania||M.D.||School of Medicine||2006|
Awards and Honors
Clinical Scientist Development Award, Doris Duke Charitable Foundation, 2015-2018
Pilot for Junior Investigators in Basic and Clinical/Translational Sciences, UCSF CTSI, 2015-2016
Centers of Excellence in Patient Research Pilot Award, UCSF Department of Medicine, 2014-2015
K23 Career Development Award, NIH NIDDK, 2013-2018
Recent Articles (20)
Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, Mifflin T, Waikar SS, Sabbisetti VS, Bonventre JV, Coresh J, Nelson RG, Kimmel PL, Kusek JW, Rahman M, Schelling JR, Vasan RS, Liu KD. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. Clin J Am Soc Nephrol. 2017 Mar 02.
Park M, Shlipak MG, Thiessen-Philbrook H, Garg AX, Koyner JL, Coca SG, Parikh CR. Association of Peak Changes in Plasma Cystatin C and Creatinine With Death After Cardiac Operations. Ann Thorac Surg. 2016 Apr; 101(4):1395-401.
Park M, Shlipak MG, Vittinghoff E, Katz R, Siscovick D, Sarnak M, Lima JA, Hsu CY, Peralta CA. Associations of kidney injury markers with subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Clin Nephrol. 2015 Dec; 84(12):358-63.
Bansal N, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, Cai J, Hunsicker LG, Park M, Bennett M, Liu KD, Hsu CY. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol. 2016 Jul; 27(7):2109-21.
Park M, Kulkarni A, Beatty A, Ganz P, Regan M, Vittinghoff E, Whooley M. Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study. Atherosclerosis. 2015 Dec; 243(2):546-52.
Wu EH, Wojciechowski D, Chandran S, Yeh BM, Park M, Westphalen A, Wang ZJ. Prevalence of abdominal aortic calcifications in older living renal donors and its effect on graft function and histology. Transpl Int. 2015 Oct; 28(10):1172-8.
Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, Park M, Sarnak M, Seliger S, Shlipak M. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015 Feb 6; 10(2):205-14.
Chong KC, Owens CD, Park M, Alley HF, Boscardin WJ, Conte MS, Gasper WJ, Grenon SM. Relationship between kidney disease and endothelial function in peripheral artery disease. J Vasc Surg. 2014 Dec; 60(6):1605-11.
Park M, Vittinghoff E, Shlipak MG, Mishra R, Whooley M, Bansal N. Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study. Am Heart J. 2014 Dec; 168(6):931-9.e2.
Parikh CR, Butrymowicz I, Yu A, Chinchilli VM, Park M, Hsu CY, Reeves WB, Devarajan P, Kimmel PL, Siew ED, Liu KD. Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis. 2014 Apr; 63(4):567-72.
Park M, Vittinghoff E, Ganz P, Peralta CA, Whooley M, Shlipak MG. Role of soluble endothelial cell-selective adhesion molecule biomarker in albuminuria and kidney function changes in patients with coronary artery disease: the Heart and Soul Study. Arterioscler Thromb Vasc Biol. 2014 Jan; 34(1):231-6.
Park M, Vittinghoff E, Liu KD, Shlipak MG, Hsu CY. Urine Biomarkers Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) Have Different Patterns in Heart Failure Exacerbation. Biomark Insights. 2013; 8:15-8.
Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012 Oct; 23(10):1725-34.
Park M, Shlipak MG, Katz R, Agarwal S, Ix JH, Hsu CY, Peralta CA. Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2012 Jul; 7(7):1137-44.
Park M, Coca SG, Nigwekar SU, Garg AX, Garwood S, Parikh CR. Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Am J Nephrol. 2010; 31(5):408-18.
Park M, Hryniewicz K, Setaro JF. Pheochromocytoma presenting with myocardial infarction, cardiomyopathy, renal failure, pulmonary hemorrhage, and cyclic hypotension: case report and review of unusual presentations of pheochromocytoma. J Clin Hypertens (Greenwich). 2009 Feb; 11(2):74-80.